Evidence level: B
上一篇文章审计了体质工具变量”够不够硬”,本文裁决一个更基础的问题:把痰湿、阳虚、阴虚三质推到万人级样本量,全基因组显著位点经 LD 修剪后还能剩下几把独立的”枪”——够不够双样本孟德尔随机化开火的最低门槛。
正文
孟德尔随机化(MR)用遗传位点当”工具变量”(IV)去推”体质→疾病”的因果,这套逻辑的前提,是手里得有一批彼此独立、且都够强的遗传位点。上一篇文章解决了”够不够硬”(F 统计量与多效性),本文回答另一个维度——”够不够多”。专业上叫 IV 密度:不是有一个全基因组显著的 SNP 就能跑双样本 MR,而是要有一组在连锁不平衡(LD)修剪后互相独立的位点。密度越高,因果估计越稳,越经得起 MR-Egger、加权中位数、留一法这一整套敏感性分析的折腾;密度太低,连多效性检验都做不了——MR-PRESSO 这类纠错工具本质上是靠”多把工具互相印证”来发现污染位点的,只有两三个 IV 时它们几乎没有功效。
先盘一下体质领域现有的”弹药存量”,结论不乐观。韩国四象体质 GWAS 用了 1222 人、扫描 34 万个位点,最强的关联停在 10⁻⁶ 量级(PMID 22394158),远够不到全基因组显著线 5×10⁻⁸;中医阳虚体质的小样本 GWAS 只有 30 对 30 人,以 p<10⁻⁴ 划线的 42 个 SNP 里没有一个接近全基因组显著(PMID 25533513);瘀滞体质在 947 名 2 型糖尿病患者中筛出 22 个 SNP,最强者 PON2 也停留在候选层面(PMID 26169365);痰湿体质最扎实的证据是基因表达谱与全基因组甲基化特征(PMID 23548117, 29518789),压根不是 GWAS 位点。换句话说,九种体质到目前为止还没有一个达到全基因组显著的稳健位点,IV 密度是零。
要把密度从零抬到能用的量级,样本量要多大?方法学给出的答案很具体。Pierce 等人(PMID 20813862)用模拟证明:多工具 MR 在多数现实场景下需要 n>1000、常常要 n>10000,否则哪怕只有五六个独立 IV 也会掉进”弱工具”陷阱;他们同时给出了 F 统计量与样本量的换算关系——F 与 R² 和样本量直接挂钩,万人级样本配上常见的遗传力估计,才能让一批位点集体跨过 F>10 的实用门槛。Burgess 与 Thompson(PMID 21414999)则指出 F>10 这条流行规则本身具有误导性——弱工具偏倚随期望 F 连续变化,事后按实测 F 挑工具还会放大偏倚,所以裁决里必须预设 F 阈值、禁止事后挑选。而 GWAS 十五周年回顾(PMID 36634672)给了更宏观的参照:样本量每上一个台阶,平均每篇研究发现的显著位点数量级就明显上升。这正说明”万人级 + 全基因组显著”是让 IV 密度突破门槛的现实路径,而不是空谈。
于是裁决设计可以定死成四条:第一步,把痰湿、阳虚、阴虚三个证据最厚的体质各做到 N≥10000 的 GWAS,统一 5×10⁻⁸ 阈值,案例-对照配比按各质人群占比换算有效样本量;第二步,对每个显著位点逐点计算第一阶段 F 统计量,剔除 F 过弱的”钝刀”;第三步,用 r²<0.01 做 LD 修剪,统计剩下的独立 IV 数量——这步尤其关键,因为同一基因座上的多个显著 SNP 往往只是同一个信号的”回声”,数出来的独立信号才是真弹药;第四步,与韩国四象的千人级 IV 集(PMID 22394158,顶多在 10⁻⁶ 量级)做强度对比,并用功效分析回答”如果达不到,差在样本量还是差在遗传架构”。判读规则提前定死:独立 IV≥10 且平均 F 显著高于 10 → 突破门槛,体质 MR 正式立项;IV 只有个位数 → 退回等位基因评分或代理表型路线;IV 为零 → 承认体质目前不具备因果推断的遗传基础,先回表型聚类与多组学。
如果密度裁决的结果是”不够”,还有两条备选路线值得写进预案。其一是等位基因评分:即使单个位点都达不到全基因组显著,也可以把一批 p 值较低、方向一致的位点合成一个评分当单工具用——Burgess 与 Thompson 的模拟(PMID 21414999)显示正确设定的评分可以规避弱工具偏倚,但代价是无法做多效性检验,且”从同一份数据里挑位点造评分”会引入严重偏倚。其二是代理表型:用肥胖、血脂、血糖这些与体质高度共线的表型的大型公开 GWAS(动辄数十万人)先跑通”代谢表型→疾病”的 MR,再反推体质特异信号的密度上限——但这是绕路,体质本身的位置会被代理表型占据。
韩国团队已经沿着这条路走到了第四步——2024 年他们用四象体质的遗传位点做双样本 MR,发现太阴型显著推高心源性栓塞性卒中风险(β=4.19)、少阴型显著压低(β=−9.34)(PMID 38927518)。这证明”体质 MR”不是幻想,但反过来也暴露了 IV 密度这个瓶颈:四象体质能跑通,很大程度上靠的是韩国体质研究十年以上的队列与基因分型积累。中医九种体质若想复现这条路,万人级 GWAS 就是绕不开的第一块多米诺骨牌——而这恰恰是”IV 密度裁决”要回答的第一道题。
证据与局限
已验证: 多工具 MR 的样本量与工具强度门槛有直接方法学证据(PMID 20813862 的 n>1000 常需 >10000;PMID 21414999 的弱工具偏倚与 F>10 误导性);GWAS 样本量与显著位点数量级同步上升有十五周年全局回顾支撑(PMID 36634672);四象体质已用遗传位点跑通双样本 MR 并得出显著因果效应(PMID 38927518)。
部分验证: 九种体质现有遗传证据停留在候选位点/表达谱层面,无全基因组显著位点(PMID 25533513, 26169365, 23548117, 29518789);韩国四象千人级 GWAS 最强信号仅 10⁻⁶ 量级(PMID 22394158),IV 密度不足。
待验证: ①痰湿/阳虚/阴虚三质在 N≥10000 时究竟能产出多少个全基因组显著位点与 LD 修剪后独立 IV;②若 IV 密度不足,用肥胖/血脂等代理表型的大规模 GWAS 能否反推体质 IV 密度的上限;③四象体质已跑通的 MR 路径(PMID 38927518)能否在中医九种体质上复现,其 IV 数量与强度是否达标。
相关阅读
- 体质工具变量强度审计:九种体质要闯过孟德尔随机化的三道闸门
- 体质作暴露:孟德尔随机化如何把”体质→疾病”从相关变成因果
- 中医九种体质的多中心GWAS重复验证
- 中医体质=遗传学基础
- 生物频率密码研究池子
证据等级: B
参考文献: PMID 20813862, PMID 21414999, PMID 36634672, PMID 38927518, PMID 22394158, PMID 25533513, PMID 26169365, PMID 23548117, PMID 29518789
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Is the Genetic \”Ammunition\” Sufficient for Mendelian Randomization in Phenotypes? An Assessment of IV Density Based on Nine Phenotype-Specific GWAS with Over 100,000 Individuals
Evidence level: B
The previous article audited whether constitution instrument variables are “hard enough.” This article addresses a more fundamental question: pushing phlegm-dampness, yang deficiency, and yin deficiency into million-person sample sizes, how many independent “guns” remain after LD pruning following whole-genome significant loci—enough to meet the minimum threshold for two-sample Mendelian randomization.
Main Text
Mendelian randomization (MR) uses genetic loci as “instrumental variables” (IVs) to infer causality from “constitution → disease.” The logic presupposes a set of genetic loci that are mutually independent and sufficiently strong. The previous article addressed “hard enough” (F-statistic and pleiotropy); this article answers another dimension—”enough in number.” Professionally termed IV density: having one whole-genome significant SNP does not suffice for two-sample MR; rather, a set of loci must be mutually independent after linkage disequilibrium (LD) pruning. Higher density yields more stable causal estimates and withstands the rigors of sensitivity analyses like MR-Egger, weighted median, and leave-one-out; lower density renders even pleiotropy testing impossible—tools like MR-PRESSO rely on “multiple instruments corroborating each other” to identify contaminated loci, and they lack power with only two or three IVs.
First, let’s inventory the existing “ammunition stock” in the constitution field; the conclusion is not optimistic. The Korean four-constitution GWAS used 1,222 individuals and scanned 340,000 loci, with the strongest association stopping at the $10^{-6}$ level (PMID 22394158), far below the whole-genome significance threshold of $5 \times 10^{-8}$; the small-sample GWAS for TCM yang deficiency constitution had only 30 pairs of 30 individuals, and among the 42 SNPs marked with $p < 10^{-4}$, none approached whole-genome significance (PMID 25533513); the stagnation constitution identified 22 SNPs in 947 type 2 diabetes patients, with the strongest, PON2, remaining at a candidate level (PMID 26169365); the most robust evidence for phlegm-dampness constitution lies in gene expression profiles and whole-genome methylation features (PMID 23548117, 29518789), not GWAS loci. In short, none of the nine constitutions has yet reached a robust whole-genome significant locus; IV density is zero.
To raise density from zero to a usable magnitude, how large must the sample size be? Methodological answers are specific. Pierce et al. (PMID 20813862) used simulations to demonstrate that multi-instrument MR typically requires $n > 1,000$, often $n > 10,000$, in most realistic scenarios; otherwise, even five or six independent IVs fall into the “weak instrument” trap. They simultaneously provide the conversion relationship between F-statistics and sample size—F is directly linked to $R^2$ and sample size, allowing a cohort of loci to collectively cross the practical threshold of $F > 10$ only with million-person samples and common heritability estimates. Burgess and Thompson (PMID 21414999) note that the popular rule of $F > 10$ itself is misleading—weak instrument bias varies continuously with expected F, and post-hoc selection based on measured F can amplify bias; thus, verdicts must preset an F threshold and prohibit post-hoc selection. Meanwhile, the fifteen-year GWAS review (PMID 36634672) provides a broader reference: with each step up in sample size, the order of magnitude of significant loci discovered per study rises markedly. This confirms that “million-person scale + whole-genome significance” is the realistic path to breaking the IV density threshold, not empty talk.
Therefore, the verdict design can be fixed at four steps: First, achieve GWAS for phlegm-dampness, yang deficiency, and yin deficiency with $N \ge 10,000$ each, applying a unified $5 \times 10^{-8}$ threshold, calculating effective sample sizes based on case-control ratios adjusted for population proportions of each constitution; Second, calculate the first-stage F-statistic for every significant locus individually, discarding “dull knives” with weak F values; Third, perform LD pruning using $r^2 < 0.01$ and count the remaining independent IVs—this step is crucial, as multiple significant SNPs on the same gene locus are often just “echoes” of the same signal; only counted independent signals constitute real ammunition; Fourth, compare intensity with the Korean four-constitution thousand-person IV set (PMID 22394158, capped at the $10^{-6}$ level) and use power analysis to answer whether the shortfall lies in sample size or genetic architecture. Interpretation rules are preset: Independent IVs $\ge 10$ and average F significantly higher than 10 → threshold broken, constitution MR formally initiated; IVs only in single digits → retreat to allele scoring or proxy phenotype routes; IVs equal zero → acknowledge that constitutions currently lack a genetic basis for causal inference, return to phenotype clustering and multi-omics.
If the density verdict results in “insufficient,” two alternative routes deserve inclusion in the contingency plan. The first is allele scoring: even if individual loci fail whole-genome significance, a batch of low p-value loci with consistent direction can be synthesized into a score used as a single instrument—Burgess and Thompson’s simulations (PMID 21414999) show that correctly specified scores can avoid weak instrument bias, but the cost is an inability to perform pleiotropy testing, and “selecting loci from the same dataset to create a score” introduces severe bias. The second is proxy phenotypes: run MR using large public GWAS for phenotypes highly correlated with constitution (such as obesity, lipids, blood sugar), often involving hundreds of thousands of individuals, to establish “metabolic phenotype → disease” MR first, then infer the density ceiling of constitution-specific signals—yet this is a detour where the constitution itself occupies the position held by the proxy phenotype.
The Korean team has already walked this path to the fourth step—In 2024, they used four-constitution genetic loci for two-sample MR, finding that the Taiyin type significantly increased risk of cardioembolic stroke ($\beta = 4.19$) while the Shaoyin type significantly decreased it ($\beta = -9.34$) (PMID 38927518). This proves “constitution MR” is not fantasy, but conversely exposes the bottleneck of IV density: the four-constitution constitution can run successfully largely due to over a decade of cohort and genotyping accumulation in Korean constitution research. For TCM nine constitutions to replicate this path, a million-person GWAS is the first domino that cannot be avoided—precisely the first question the “IV density verdict” must answer.
Evidence and Limitations
Verified: Methodological evidence directly links sample size and instrument strength thresholds for multi-instrument MR (PMID 20813862 shows $n > 1,000$ often requires $> 10,000$; PMID 21414999 shows misleading nature of weak instrument bias and $F > 10$); fifteen-year global review supports synchronous rise in significant locus magnitude with sample size (PMID 36634672); four-constitution constitution has successfully run two-sample MR using genetic loci yielding significant causal effects (PMID 38927518).
Partially Verified: Current genetic evidence for nine constitutions remains at candidate loci/expression profile levels with no whole-genome significant loci (PMID 25533513, 26169365, 23548117, 29518789); Korean four-constitution thousand-person GWAS strongest signal only at $10^{-6}$ level (PMID 22394158), IV density insufficient.
To Be Verified: ① How many whole-genome significant loci and LD-pruned independent IVs can phlegm-dampness/yang deficiency/yin deficiency produce at $N \ge 10,000$; ② If IV density is insufficient, can large-scale GWAS using proxy phenotypes like obesity/lipids infer the upper limit of constitution IV density; ③ Can the MR path already validated in four-constitution (PMID 38927518) be replicated in TCM nine constitutions, and do IV counts and intensity meet standards.
Related Reading
- Constitution Instrument Variable Strength Audit: Nine Constitutions Must Pass Three Gates of Mendelian Randomization
- Constitution as Exposure: How Mendelian Randomization Turns “Constitution → Disease” from Correlation to Causality
- Multi-center GWAS Replication of TCM Nine Constitutions
- TCM Constitution = Genetic Basis
- Biological Frequency Research Pool
Evidence Level: B
References: PMID 20813862, PMID 21414999, PMID 36634672, PMID 38927518, PMID 22394158, PMID 25533513, PMID 26169365, PMID 23548117, PMID 29518789
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply